Seeking AlphaCodex · 实盘不做把握 6/10
北京时间·🕒 发布 23:18:44时区推断·⟳ 抓取 23:19:23·⚡ 决策 07-23 23:21:46 +2m23s·96.0 天前
Medpace二季度业绩超预期并上调全年指引，带动CRO板块盘中上涨
Medpace二季度收入7.073亿美元、EPS 4.25美元均高于预期，全年收入和EPS指引也高于FactSet共识，事件本身对MEDP为正面。
📄 原文Seeking Alpha↗ 原文
Medpace leads a rally in CRO space after Q2 beat
Shares of Medpace Holdings (MEDP) climbed, and its rival contract research organizations also traded higher after the c…
不做 Medpace Holdings（MEDP.US）
财报利好成立但一手财报已于2026-07-22盘后披露，2026-07-23盘中已涨约15%至18%并创52周高位，当前不追财报后高位跳涨。
不做 IQVIA Holdings（IQV.US）
只是MEDP业绩带动的CRO同业情绪联动，IQVIA自身尚无新业绩或指引增量，缺少公司级可量化edge。
不做 ICON Public Limited（ICLR.US）
同业跟涨缺少ICON自身订单、收入或指引确认，不能用MEDP单家公司超预期直接外推下单。
不做 Charles River Laboratories（CRL.US）
板块beta反应强于公司级催化，当前没有CRL自身新增正面事实，做多胜率不足。
不做 Fortrea Holdings（FTRE.US）
FTRE跟涨来自CRO板块情绪，缺少自身基本面确认且盘中已被带动反应，不做sympathy追价。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- Medpace官方披露Q2收入、EPS、净新增业务和2026全年指引，构成本次利好的一手来源。
- 公司安排2026-07-23 09:00 ET召开业绩电话会，盘前已给市场进一步消化窗口。
- 财经媒体报道MEDP盘中约18%上涨，并指出book-to-bill明显好于市场预期。市场反应:MEDP已大幅上涨至52周高位。
- Seeking Alpha在盘中报道MEDP上涨并带动CRO同业走强，属于对已发布财报和已发生价格反应的扩散。市场反应:MEDP涨逾15%，IQV、ICLR、CRL、FTRE等同业跟涨。
关键理由
- Medpace二季度收入7.073亿美元、EPS 4.25美元均高于预期，全年收入和EPS指引也高于FactSet共识，事件本身对MEDP为正面。
- 但公司官方财报已在2026-07-22盘后发布，2026-07-23美股盘中MEDP已上涨约15%至18%并创52周高位，Seeking Alpha信号更像盘中复述市场反应。
- IQVIA、ICON、Charles River和Fortrea只是同业情绪联动，尚未披露自身业绩，不能把MEDP的单家公司超预期直接外推为可量化同向交易。
主要风险
- 追MEDP属于财报后大幅跳空后追高，容易遇到高开高走后的获利了结或分析师维持中性评级。
- 同业CRO跟涨缺少自身订单或指引确认，若后续各家公司财报不跟随超预期，sympathy trade的edge较弱。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-23 · 影响 weakens
媒体报道显示Leerink和William Blair仍维持market perform，市场关注该反弹能否持续到2027年，削弱追高确定性。
检索:Medpace Q2 2026 earnings analysts market perform sustainability rebound 2027 growth 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-22 · 影响 weakens
一手财报在前一日盘后已发布，当前信号到达时MEDP已大幅上涨，新增交易窗口质量下降。
检索:Medpace Q2 2026 results official release July 22 2026 guidance consensus 原文 ↗
原文全文
展开原文 · 1,233 字
Shares of Medpace Holdings (MEDP) climbed, and its rival contract research organizations also traded higher after the company reported Q2 2026 financials and provided full-year guidance exceeding Street forecasts.
Medpace (MEDP) added more than 15%, recording its best intraday rally in a year to reach a 52-week high. Its CRO peers, including IQVIA Holdings (IQV), ICON Public Limited (ICLR), Charles River Laboratories (CRL), and Fortrea Holdings (FTRE), which are yet to report their latest financials, were among the notable gainers.
The upsurge came after Cincinnati, Ohio-based Medpace (MEDP) reported $707.3M in revenue for Q2, exceeding the consensus by $18.5M with ~17% YoY growth. Its earnings per share also topped the estimates by $0.26 to reach $4.25 with a ~37% YoY rise.
The company attributed the topline performance to an improved backlog conversion rate, which reached 24.1% compared with 21.2% in the prior-year period. Its net new business awards stood at $797.5M with a net book-to-bill ratio of 1.13x, compared with 1.03x in Q2 2025.
Looking ahead, Medpace (MEDP) set its 2026 outlook for revenue and GAAP EPS at $2.805B-$2.885B and $17.25-$17.95, exceeding $2.77B and $16.97 in FactSet consensus, respectively.
Medpace (MEDP) added more than 15%, recording its best intraday rally in a year to reach a 52-week high. Its CRO peers, including IQVIA Holdings (IQV), ICON Public Limited (ICLR), Charles River Laboratories (CRL), and Fortrea Holdings (FTRE), which are yet to report their latest financials, were among the notable gainers.
The upsurge came after Cincinnati, Ohio-based Medpace (MEDP) reported $707.3M in revenue for Q2, exceeding the consensus by $18.5M with ~17% YoY growth. Its earnings per share also topped the estimates by $0.26 to reach $4.25 with a ~37% YoY rise.
The company attributed the topline performance to an improved backlog conversion rate, which reached 24.1% compared with 21.2% in the prior-year period. Its net new business awards stood at $797.5M with a net book-to-bill ratio of 1.13x, compared with 1.03x in Q2 2025.
Looking ahead, Medpace (MEDP) set its 2026 outlook for revenue and GAAP EPS at $2.805B-$2.885B and $17.25-$17.95, exceeding $2.77B and $16.97 in FactSet consensus, respectively.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。